Skip to content

BioSenic (formerly Bone Therapeutics) uploaded a News Release
December 20, 2019


Bone Therapeutics advances JTA-004 into pivotal Phase III study

  • Clinical trial application for pivotal JTA-004 Phase III study submitted
  • Start patient enrollment anticipated early 2020 with topline results expected in Q2 2021
  • The JTA-004 Phase III study is a placebo and active-controlled, randomized, double-blind study to evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20

Jean Stéphenne, Chairman of Bone Therapeutics commented: “Following the promising safety and efficacy results from the previous study with JTA-004, we are pleased that the Clinical Trial Application for the Phase III study is now being submitted. Based on its unique composition, JTA-004 could offer an improved treatment option to the numerous patients suffering from knee osteoarthritis. The CTA filing is an important milestone in the development of this core pipeline asset and we look forward to starting enrolling patients in this study in the first months of 2020.”

About Us | Please read our Privacy Policy, Cookie Policy, Disclaimer and Terms and Conditions. By accessing or using the Service you agree to be bound by these Terms. © 2024 Arrowhed Business and Investment Decisions, LLC.